FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 Instruction 1(b)

Name and Address of Reporting Person* Ragosa Mark						2. Issuer Name and Ticker or Trading Symbol Kiniksa Pharmaceuticals International, plc [KNSA]								eck all applic Directo	cable)	g Person(s) to Is 10% C Other				
(Last) (First) (Middle)						3. Date of Earliest Transaction (Month/Day/Year) 07/23/2024								below)	.0	CIAI	below) L OFFICE	` '		
23 OLD BOND STREET, THIRD FLOOR						4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)						
(Street) LONDON X0 W1S 4PZ				Z	_									Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City) (State) (Zip)				R	Rule 10b5-1(c) Transaction Indication															
					7	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tab	le I - No	on-Deri	vativ	e Se	curit	ties Ac	quired	, Dis	sposed o	f, or Be	neficial	ly Owned	i					
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day						Execution Date			Transaction Disposed O Code (Instr.			es Acquired (A) or Of (D) (Instr. 3, 4 and 5)		Securiti Benefic Owned	5. Amount of Securities Beneficially Owned Following		n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)		
Class A Ordinary Share 07/23/2					3/2024	/2024					24,248	A	\$11.1	1 43,501		D				
Class A Ordinary Share 07/23/2					3/2024	2024					24,248	D	\$24.79	(2) 19	,253		D			
		•	Table II								osed of, convertil			Owned						
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deem Execution if any (Month/D	n Date,	4. Transa Code (8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s Illy	Ownershi Form: Direct (D) or Indirec (I) (Instr. 4	Beneficial Ownership t (Instr. 4)		
					Code	v	(A)	(D)	Date Exercisa	able	Expiration Date	Title	Amount or Number of Shares							
Share Option	\$11.1	07/23/2024			M ⁽¹⁾			24,248	(3)		04/06/2032	Class A Ordinary	24,248	\$0	40,41	2	D			

Explanation of Responses:

- 1. This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging between \$24.72 and \$25.095. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- 3. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.

/s/ Madelyn Zeylikman, Attorney-in-Fact

07/25/2024

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.